Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$26.04
+1.4%
$26.62
$23.11
$28.75
$146.42B0.3431.71 million shs31.84 million shs
Banco Santander, S.A. stock logo
SAN
Banco Santander
$12.16
-2.5%
$12.03
$7.83
$13.24
$183.18B0.738.12 million shs8.23 million shs
Sanofi stock logo
SNY
Sanofi
$45.02
+1.4%
$45.45
$42.28
$52.68
$107.60B0.342.53 million shs2.60 million shs
Sanofi stock logo
SNYNF
Sanofi
$87.71
+1.3%
$90.36
$83.17
$106.34
N/AN/A21,962 shs29,479 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+1.34%-0.53%-1.76%-3.79%+11.20%
Banco Santander, S.A. stock logo
SAN
Banco Santander
-2.57%-2.41%-1.94%+9.80%+54.45%
Sanofi stock logo
SNY
Sanofi
+1.44%+3.09%+2.86%+1.05%-9.05%
Sanofi stock logo
SNYNF
Sanofi
+1.26%+1.18%+1.61%-2.04%-9.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$26.04
+1.4%
$26.62
$23.11
$28.75
$146.42B0.3431.71 million shs31.84 million shs
Banco Santander, S.A. stock logo
SAN
Banco Santander
$12.16
-2.5%
$12.03
$7.83
$13.24
$183.18B0.738.12 million shs8.23 million shs
Sanofi stock logo
SNY
Sanofi
$45.02
+1.4%
$45.45
$42.28
$52.68
$107.60B0.342.53 million shs2.60 million shs
Sanofi stock logo
SNYNF
Sanofi
$87.71
+1.3%
$90.36
$83.17
$106.34
N/AN/A21,962 shs29,479 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+1.34%-0.53%-1.76%-3.79%+11.20%
Banco Santander, S.A. stock logo
SAN
Banco Santander
-2.57%-2.41%-1.94%+9.80%+54.45%
Sanofi stock logo
SNY
Sanofi
+1.44%+3.09%+2.86%+1.05%-9.05%
Sanofi stock logo
SNYNF
Sanofi
+1.26%+1.18%+1.61%-2.04%-9.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfizer Inc. stock logo
PFE
Pfizer
2.20
Hold$28.8210.68% Upside
Banco Santander, S.A. stock logo
SAN
Banco Santander
2.50
Moderate BuyN/AN/A
Sanofi stock logo
SNY
Sanofi
2.47
Hold$51.0013.28% Upside
Sanofi stock logo
SNYNF
Sanofi
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PFE, SNY, SNYNF, and SAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/1/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingNeutral
5/27/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingNeutral$27.00
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/13/2026
Sanofi stock logo
SNY
Sanofi
UpgradeSell (D+)Hold (C-)
5/12/2026
Banco Santander, S.A. stock logo
SAN
Banco Santander
Reiterated RatingOutperform
5/8/2026
Banco Santander, S.A. stock logo
SAN
Banco Santander
DowngradeBuy (A-)Buy (B+)
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/5/2026
Banco Santander, S.A. stock logo
SAN
Banco Santander
Reiterated RatingBuy
5/1/2026
Sanofi stock logo
SNY
Sanofi
Set Price Target$52.00
5/1/2026
Sanofi stock logo
SNY
Sanofi
DowngradeOverweightEqual Weight
4/30/2026
Banco Santander, S.A. stock logo
SAN
Banco Santander
Reiterated RatingOverweight
(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfizer Inc. stock logo
PFE
Pfizer
$63.31B2.34$4.46 per share5.84$15.26 per share1.71
Banco Santander, S.A. stock logo
SAN
Banco Santander
$66.36B2.69$1.28 per share9.50$8.57 per share1.42
Sanofi stock logo
SNY
Sanofi
$49.35B2.21$7.17 per share6.28$33.26 per share1.35
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.889.11N/A11.83%19.44%8.41%8/4/2026 (Estimated)
Banco Santander, S.A. stock logo
SAN
Banco Santander
$15.95B$1.2110.059.420.7126.92%12.23%0.74%7/22/2026 (Estimated)
Sanofi stock logo
SNY
Sanofi
$8.84B$3.5812.588.641.0916.95%13.39%7.58%7/30/2026 (Estimated)
Sanofi stock logo
SNYNF
Sanofi
N/A$3.0828.44N/AN/AN/AN/AN/AN/A

Latest PFE, SNY, SNYNF, and SAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/29/2026Q1 2026
Banco Santander, S.A. stock logo
SAN
Banco Santander
$0.29$0.2660-$0.0240$0.42$17.66 billion$17.53 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.60%-13.20%131.30%16 Years
Banco Santander, S.A. stock logo
SAN
Banco Santander
$0.211.73%N/A17.36%N/A
Sanofi stock logo
SNY
Sanofi
$1.763.91%+6.46%49.16%N/A
Sanofi stock logo
SNYNF
Sanofi
$2.803.19%N/A90.78%N/A

Latest PFE, SNY, SNYNF, and SAN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
4/14/2026
Sanofi stock logo
SNY
Sanofi
annual$2.42255.59%5/4/20265/4/20266/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
Banco Santander, S.A. stock logo
SAN
Banco Santander
N/A
0.25
0.25
Sanofi stock logo
SNY
Sanofi
0.17
1.01
0.22
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Banco Santander, S.A. stock logo
SAN
Banco Santander
9.19%
Sanofi stock logo
SNY
Sanofi
14.03%
Sanofi stock logo
SNYNF
Sanofi
30.06%

Insider Ownership

CompanyInsider Ownership
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Banco Santander, S.A. stock logo
SAN
Banco Santander
9.48%
Sanofi stock logo
SNY
Sanofi
1.00%
Sanofi stock logo
SNYNF
Sanofi
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Banco Santander, S.A. stock logo
SAN
Banco Santander
198,40314.69 billion13.30 billionOptionable
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable
Sanofi stock logo
SNYNF
Sanofi
91,600N/AN/ANot Optionable

Recent News About These Companies

UBS Keeps Their Hold Rating on Sanofi (SNYNF)
Sanofi (SNYNF) Gets a Hold from J.P. Morgan
Deutsche Bank Reaffirms Their Buy Rating on Sanofi (SNYNF)
UBS downgrades Sanofi (SNYNF) to a Hold
Berenberg Bank Sticks to Their Buy Rating for Sanofi (SNYNF)
Leerink Partners Reaffirms Their Buy Rating on Sanofi (SNYNF)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Pfizer stock logo

Pfizer NYSE:PFE

$26.04 +0.35 (+1.37%)
Closing price 06/5/2026 03:59 PM Eastern
Extended Trading
$25.97 -0.08 (-0.29%)
As of 06/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Banco Santander stock logo

Banco Santander NYSE:SAN

$12.16 -0.32 (-2.53%)
Closing price 06/5/2026 03:59 PM Eastern
Extended Trading
$12.28 +0.12 (+0.99%)
As of 06/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Banco Santander, S.A. provides various financial services worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, mutual funds, and current and savings accounts; mortgages, consumer finance, loans, and various financing solutions; and project finance, debt capital markets, global transaction banking, and corporate finance services. The company also provides asset management and private banking services; and insurance products. In addition, it offers corporate and investment banking services; and digital payment solutions. Further, it offers online banking and financial services to retail, business, institutional, corporate, private banking and university customers and clients. The company was formerly known as Banco Santander Central Hispano SA and changed its name to Banco Santander, S.A. in February 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.

Sanofi stock logo

Sanofi NASDAQ:SNY

$45.02 +0.64 (+1.44%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$44.92 -0.11 (-0.23%)
As of 06/5/2026 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi stock logo

Sanofi OTCMKTS:SNYNF

$87.71 +1.09 (+1.26%)
As of 06/5/2026 11:33 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.